Immutrin raised a £65M ($87M) Series A to develop an antibody therapy for ATTR amyloidosis.
Immutrin is a biotechnology company developing next generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis
Immutrin is a biotechnology company developing next generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis. The Company’s lead asset is being developed for the treatment of ATTR cardiomyopathy, a serious and progressive form of amyloidosis.